Read More

Alnylam Earlier Announced Updates To The Statistical Analysis Plan For The HELIOS-B Phase 3 Study Of Vutrisiran; Will Include Updates To The Primary And Secondary Endpoint Structure; Topline Results Are Expected To Be Available In Late June Or Early Ju…

R&D HighlightsAlnylam announces today updates to the statistical analysis plan for the HELIOS-B Phase 3 study of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy. These will include updates to the

ALNY